ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
about
Tumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsModels incorporating chromatin modification data identify functionally important p53 binding sitesGlobal analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms.A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response.Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseasesIntegrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis.Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.MDM2, MDMX and p53 in oncogenesis and cancer therapyATM signalling and cancer.Development of synthetic lethality anticancer therapeutics.Computational methods and opportunities for phosphorylation network medicineIdentification of potential synthetic lethal genes to p53 using a computational biology approachK-Map: connecting kinases with therapeutics for drug repurposing and developmentWild type p53 reactivation: from lab bench to clinic.edgeR: a versatile tool for the analysis of shRNA-seq and CRISPR-Cas9 genetic screens.ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels.Human ACAP2 is a homolog of C. elegans CNT-1 that promotes apoptosis in cancer cellsThe impact of post-transcriptional regulation in the p53 network.Tetraploidization or autophagy: The ultimate fate of senescent human endometrial stem cells under ATM or p53 inhibitionTrisomy 21 consistently activates the interferon response.Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?The kinome 'at large' in cancer.Regulation of the MET oncogene: molecular mechanisms.The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity.Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299.Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerA genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation.CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activitySMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stressIdentification of synthetic lethal pairs in biological systems through network information centrality.Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.
P2860
Q26801410-267E3A00-0717-46E7-BB05-6E7B936395F1Q30618656-7E464370-0DDC-4D77-ACF8-E308BECEAEBFQ33659512-30FBC227-4A3B-4607-A9BA-C273820F6378Q33804888-425FEBA3-E980-4607-B11A-7C1D47111EF2Q33909288-BC9195E5-C0D5-44D8-9B92-CA5D6008E9ADQ34038417-B113D04F-06D2-490F-B667-CF13328D0B1EQ34103108-11F59A41-1D9C-47A6-BE9A-DA3E10F7F222Q34166049-B37891E2-821D-4D9E-A7C4-719F71F5F355Q34357377-2DED9A82-A92C-468D-91BB-E351080AF232Q34380368-6DC43B09-7655-4E58-B549-6A79C6A7E8C8Q34742859-F3DF14B4-8FD8-4AF9-87ED-05F8C2B1F990Q34985284-16E7AE39-5FA6-474D-A60E-7C7699D17B9AQ34995806-7CA4D87E-903C-4876-A574-39451EAE150FQ35146343-A142129D-1E0D-4AEE-818C-959D0D8A6DFEQ35173843-BAEE4889-7759-412D-B55E-D49F55B7DC37Q36188841-81DA3102-AA41-4139-B5DC-E41132F28EABQ36189228-35AE2C32-20CE-4CE4-AC9E-4A1FD6BCDC82Q36542788-8F0A34EB-10EA-49A2-A93B-04F958A285EDQ36781235-E48A5B9B-003D-4040-91C9-088EA6F26682Q37235217-B514B826-75CE-4A21-962F-7997958296CDQ38209599-C4EECDF8-A9F8-4A4F-ACC6-E34ACD98EBC6Q38715428-C0D5EAAE-096B-4728-BF02-8B9B644956EDQ38746401-5CE63913-030F-4D64-B14F-F53D0F35F8BAQ38756911-80CCF8B9-DA8A-4795-9FF4-C8703845F59FQ38759968-08464284-13B0-4567-BAE6-8A298E8B2B0BQ38797572-5C548C73-9B21-49AB-BA29-DCF9878AEE97Q39063287-1FD42FB0-8BBA-4FF3-B443-9DF80CB5FF3BQ39140763-1B1190B0-A06C-44DD-A298-279FBD865DF8Q39150492-272AB081-33BA-4E28-9487-6D83F96F601DQ41194695-2F8425B1-6325-4F91-B442-B8ABE1BC6A45Q42275759-98008FA0-9AE4-4637-B965-DC53B796EE9EQ42293531-1EE4F522-C4E4-4B68-95ED-2F4003F097B9Q44441716-50C66F1A-211B-44FC-BAED-F093B7E6B9B2Q46006387-2D774A8B-A710-460D-8874-339E9C024419Q51176917-FE109ED5-63E9-4EBD-BD8A-7B878F251305
P2860
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@en
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@nl
type
label
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@en
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@nl
prefLabel
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@en
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@nl
P2093
P2860
P356
P1476
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
@en
P2093
Aik Choon Tan
Christopher C Porter
James DeGregori
Joaquín M Espinosa
John J Tentler
Kelly D Sullivan
Nuria Padilla-Just
Ryan E Henry
S Gail Eckhardt
P2860
P2888
P304
P356
10.1038/NCHEMBIO.965
P577
2012-06-03T00:00:00Z